diabetes

AHA 2023

AHA 2023 | SELECT Trial: Semaglutide in Patients Without Diabetes

Given the obesity pandemic projected for the year 2035, it is imperative to address this disease as a priority, through well-known hygienic-dietary measures and the use of drugs that have shown promising results. Obesity has been identified as an independent cardiovascular risk factor, even after modifying risk factors associated with diabetes. Semaglutide, a GLP-1 agonist,<a href="https://solaci.org/en/2023/11/15/aha-2023-select-trial-semaglutide-in-patients-without-diabetes/" title="Read more" >...</a>

Diabetes y enfermedad vascular periférica: viejas drogas con nueva evidencia

BIFURCAT Registry: Long Term Diabetes Impact on Bifurcations PCI Outcomes

The impact of diabetes in patients with coronary artery disease (CAD) are well known, and after percutaneous coronary intervention (PCI), outcomes tend to be less favorable, with higher restenosis rate, repeat myocardial infarction (MI) and stent thrombosis. Despite the development of drug eluting stents, procedures and techniques, treating bifurcation lesions in diabetic patients still show<a href="https://solaci.org/en/2023/09/15/bifurcat-registry-long-term-diabetes-impact-on-bifurcations-pci-outcomes/" title="Read more" >...</a>

ACC 2023 | COORDINATE-DIABETES

Approximately only 2.7% of all diabetic patients with ischemic heart disease in the United States receive optimal treatment consisting in high doses of statins (ACEI/ARAII) or cardio-stable antihyperglycemic agents such as SGLT2I and GLP-1RA (three of them). Of the population, 37.4% does not use any medication. Randomization was conducted at the healthcare facility level, rather<a href="https://solaci.org/en/2023/03/10/acc-2023-coordinate-diabetes-3/" title="Read more" >...</a>

Sugar-trial-tct2021

TCT 2021 | SUGAR Trial: Polymer-Free Stent in Diabetes

In CAD patients with diabetes the polymer-free amphilimus-eluting stent resulted non-inferior to the polymer-based zotarolimus-eluting Resolute Onyx. This new device, in addition to ultrathin struts, has already been found non-inferior to the Resolute Integrity in the general population at 3-year followup. Researchers believe that the new amphiphilic carrier might be especially useful in diabetic patients<a href="https://solaci.org/en/2021/11/09/tct-2021-sugar-trial-polymer-free-stent-in-diabetes/" title="Read more" >...</a>

Diabetes y enfermedad vascular periférica: viejas drogas con nueva evidencia

Diabetes and Peripheral Vascular Disease: Old Drugs, New Evidence

This paper, recently published in JAHA, showed that patients with type&nbsp;2 diabetes mellitus exhibiting lower-limb vascular disease benefit from combining cilostazol and clopidogrel. Treatment for at least 6&nbsp;months with clopidogrel (75&nbsp;mg/QD) plus cilostazol (100&nbsp;mg/BID) significantly reduces ischemic eventsincluding stroke, infarction, and death from vascular causescompared with clopidogrel monotherapy. Adding cilostazol reduces ischemic events, but that<a href="https://solaci.org/en/2021/01/07/diabetes-and-peripheral-vascular-disease-old-drugs-new-evidence/" title="Read more" >...</a>

Diabetes y enfermedad vascular periférica: viejas drogas con nueva evidencia

Diabetes Could Decide between Ticagrelor and Prasugrel

Diabetes has an impact on the relative effect of ticagrelor and prasugrel in patients undergoing acute coronary syndrome (ACS) according to a recent analysis of the ISAR-REACT 5 published in JACC Intv. Similarly to the main study outcomes, this sub-analysis of the ISAR-REACT 5 has shown that the combined end point of death, MI or<a href="https://solaci.org/en/2020/10/16/diabetes-could-decide-between-ticagrelor-and-prasugrel/" title="Read more" >...</a>

ACC 2020 Virtual | Sub-análisis del COMPASS: la diabetes aumenta el beneficio del rivaroxaban más AAS

Virtual ACC 2020 | COMPASS Sub-Analysis: Diabetes Increases the Benefit of Rivaroxaban Combined with AAS

In patients with stable coronary or peripheral artery disease, diabetes increases the benefit of combining low doses of rivaroxaban and aspirin vs. aspirin alone.&nbsp; This analysis was pre-specified in the COMPASS protocol and was presented virtually for the ACC 2020 and simultaneously published in Circulation. Patients with diabetes, showed numerically greater reduction in terms of<a href="https://solaci.org/en/2020/03/30/virtual-acc-2020-compass-sub-analysis-diabetes-increases-the-benefit-of-rivaroxaban-combined-with-aas/" title="Read more" >...</a>

Diabetes y enfermedad vascular periférica: viejas drogas con nueva evidencia

Reliability of FFR in Patients with Diabetes: Are Other Parameters Necessary?

Diabetes does not seem to alter the results of a fractional flow reserve (FFR) measurement in a given lesion. Recently, expert opinions and small studies had questioned the reliability of FFR in this specific patient subgroup. This new observational study soon to be published in JAMA vanquishes all doubts and confirms the efficacy of this<a href="https://solaci.org/en/2020/02/03/reliability-of-ffr-in-patients-with-diabetes-are-other-parameters-necessary/" title="Read more" >...</a>

Stent directo vs angioplastia convencional y sus interacciones con la trombo-aspiración

Revascularization in Patients with Multivessel Disease, Diabetes, and Kidney Disease

According to this new study, in patients with coronary disease, diabetes, and chronic kidney disease who underwent revascularization through angioplasty or surgery, events are similar. This is one of the first studies painting the real picture for the prognosis of patients revascularized in these conditions (diabetes plus chronic kidney disease). &nbsp; At first sight, these<a href="https://solaci.org/en/2019/03/04/revascularization-in-patients-with-multivessel-disease-diabetes-and-kidney-disease/" title="Read more" >...</a>

Top